Xpress Biologics
" Xpress Biologics, a Belgian based CDMO, has several strategies to tackle the COVID-19 pandemic which includes: - The development of a serology assay to detect Covid-19 seroconversion in humans based on the manufacturing of 3 specific COVID-19 antigens ( full-length Spike protein, S1 subunit, RBD domain) using Pichia pastoris as expression system - Plasmid DNA manufacturing expertise for the development of anti-COVID DNA vaccines - Recombinant protein or antibody fragments manufacturing expertise for diagnostic and treatment of COVID-19 Xpress Biologics has adapted technological platforms that are available to meet the COVID-19 pandemic challenge. In particular our Molecular Biology solution can rapidly help us develop microbial strains for robust and efficient expression of several type of biologics such as viral antigens, neutralizing antibody fragments and DNA vaccines while through our Upstream Process platform we can rapidly engineer industrial processes for...

Read more: Alexandre Di Paolo, Business Development Manager

Delphi Genetics SA
" The aim of the project is to develop an antiviral gene therapy specifically targeting Covid-19. The benefits should be (i) targeting precisely the virus directly in lung cells allowing limitation of virus development from the starting point, (ii) restoring essential functions of the patient's cells and (iii) antibodies production by the patient due to reduction of viral load but not immediate clearance. In addition, the therapy could also be used preventively for people who come into regular contact with affected patients. The therapy is a gene therapy using AAV for patient administration. Delphi Genetics is developing and producing the plasmids required for targeting the virus and production of AAV. "
Contact: Cedric Szpirer Delphi Genetics SA 071 25 10 00

UCLouvain - FNRS
" We developed protocols to measure the interaction between single virus and living cells and monitor the effect of blocking molecule interfering with the virus binding. "
Contact: Dr. David Alsteens UCLouvain/ LIBST This email address is being protected from spambots. You need JavaScript enabled to view it.

ULiège, GIGA
" There is no effective antiviral treatment for SARS-Cov-2 which is responsible for the current pandemic. Research efforts are therefore focused on the rapid development of vaccines and the evaluation of antiviral drugs. Testing the effectiveness of these on virus cultures is laborious and requires a BSL3 environment. In order to be able to evaluate (quickly and in safe conditions) the effectiveness of the various drugs acting against this virus, cells expressing Sars-Cov2 viral enzymes will be generated. In these cells, enzymatic activity would be easily quantifiable using a reporter system. In a first phase of our project, different FDA-approuved drugs will be tested, hoping to identify some that will be effective against viral enzymes. "
Funding: FONDATION LEON FREDERICQ
Contact: Dr. Emmanuel Di Valentin Platform manager University of LIEGE (ULiege) Giga Viral Vectors Platform Tour GIGA B34 (+4) CHU Avenue Hypocrate 1 B-4000 LIEGE (Sart Tilman) Tel. +32 (0) 4 366 45...

Read more: Emmanuel Di Valentin, Doctor

UCLouvain
" This study aims to assess the potential roles of spike glycoproteins and viral proteins encoded by ORF6, ORF7a, ORF8 and ORF10 in the antagonism of several known restriction factors (BST-2, GBP5, IFITM, ...) and in the modulation of innate immune responses (NF-kB pathway and IFN response). These proteins will be expressed in different cell models and we will define their ability to bind and/or degrade restriction factors. Depending on results, we will perform sequencing (NGS) of these genes from clinical isolates in order to observe whether the genetic variability can be linked to the pathogenesis of SARS-CoV-2 viruses. "
Funding: Own funds
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

Laboratory of Cancer Epigenetics, ULB, Faculty of Medicine - Royal Academy of Medicine of Belgium
" In recent years epigenetics has become an essential component of biological research, playing key roles in many physiopathological conditions. Recent work in viral epigenetics highlighted these modifications as an essential mechanism in modulating many viruses life cycles. To date, whether this holds true also for SARS-CoV-2 remains unknown, let alone the potential use of epigenetics inhibitors as novel antiviral therapy against SARS-CoV-2. • To address these unanswered questions and to respond to the current international urge of new therapeutic approaches against COVID-19, our study, which would uncover a link between epigenetics and SARS-CoV-2, aim to provide innovative advances for SARS-CoV-2 biology and therapy: • Overall, we will generate a comprehensive dataset aiming at expanding further our understanding of the biological functions of epigenetic modifications in the SARS-CoV-2...

Read more: François Fuks, Full Professor

UCLouvain/IREC/MBLG
" The objective of this project is to perform SARS CoV-2 infection of cells from Vero E6 line. With a view to -Study the information of the infection on the immune activation pathways and the metabolic pathways within the cells - Perform virus viability assays in different environments and analyze the effectiveness of the hygiene measures taken to prevent transmission of the virus into the environment. - Study the neutralization and the cytopathogenic effect by antibodies from clinical samples "
Funding: own funding
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it., Professor UCLouvain/Cliniques universitaires St-Luc This email address is being protected from spambots. You need JavaScript enabled to view it., PhD UCLouvain

ULiège, CHU - FNRS
" We aim to define the clinical characteristics associated with the production and the level of neutralizing antibodies (NAbs) in COVID19 recovered patients. In particular, we will investigate whether the development of a strong and persistent humoral immune response takes place in severely affected, individuals with mild symptoms or asymptomatic individuals. We will also study the study the persistence of NAbs overtime. "
Funding: Fonds Léon Frédéricq FNRS
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

UCLouvain - FNRS
" A project developed by the Université d'Etat de Haïti will be supported. Its aim will be to test the possibility that the Moringa local plant may help to dicrease severity to disease through decrease of viral replication or enhancement of patient resistance. "
Funding: ARES-CCD
Contact: Prof. J.-P. Coutelier de Duve Institute Universite Catholique de Louvain SSS/DDUV - ICP Av. Hippocrate 75, bte B1.74.05 1200 Woluwe-Saint-Lambert Belgique tel 32 2 764 7437 fax 32 2 764 7430 e-mail This email address is being protected from spambots. You need JavaScript enabled to view it.
Comment: The project is developed by the Université d'Etat de Haïti, and is supported through an Institutional Support programme of ARES-CCD by looking at possible collaborations to perform it.

Aesculape CRO Belgium BV
" Treatment of COVID 19 complications with antibodies "
Funding: partly public partly private
Contact : This email address is being protected from spambots. You need JavaScript enabled to view it. 0492 735931

UMONS, ULB, Sciensano
" A new type of biosensor to characterize in details antibodies specific for antigens of SARS-COV-2. "
Funding: UMONS
Publication References: E. Gosselin, O Denis, A. Van Cauwenberge, J. Conti, JJ Vanden Eynde, K. Huygen, J. De Coninck, "Quantification of the trichothecene Verrucarin-A in environmental samples using an antibody-based spectroscopic biosensor", Sensor Actuat. B.-Chem., 2012, 166-167, 549-555.
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

EXO Biologics
" EXO Biologics plans to extend its research and development program towards the COVID-19 crisis by using its unique and disruptive technology based on Extracellular Vesicles. These nanometer size particles are gaining momentum in the scientific community as potential alternatives to stem cell and biologic drugs therapies in the fields of immunology, neurology, oncology, cardiology, gastroenterology among others. EXO Biologics has 12 years of experience in cell-based regenerative medicine and 8 years of experience in Extracellular Vesicles. Our advancements in research will play an important role for our company mission to provide affordable and accessible therapies to patients with unmet medical needs. "
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

ULiège, CIRM, FARAH
" Several natural products (i.e. lycorine, glycyrrhizine, extracts of Pelargonium, Echinacea, Sambucus,...) have shown activity against coronaviruses. Several plants have been used in Chinese Medicine to treat patients with COVID-19. The objective of this project is to evaluate several natural products against SARS-COV2 in vitro and confirm their potential for further development. "
Funding: Own funding.
Contact: Prof Michel FREDERICH https://www.cirm.uliege.be This email address is being protected from spambots. You need JavaScript enabled to view it.

ULiège 
" There is a critical need for therapeutic solutions against SARS-CoV-2. Before implementing innovative treatments in human medicine, a first screening of the antiviral or immunomodulatory activity should be performed by in vitro and in vivo methods. To this aim, we developed in vitro (cell culture) and in vivo (hamsters and mice) models of SARS-CoV-2 infection. We developed an in vitro (cell culture) and in vivo (hamsters and mice) to screen antiviral or immunomodulatory molecules, in partnership with colleagues from the ULiège hospital and the GIGA research center. We also validate the inactivation protocols to facilitate the diagnostic workflow, in partnership with the Federal task force. "
Funding: Currently no funding. We applied to the "Crédits urgents de recherche" call.
Contact: Mutien Garigliany, DVM, PhD, Dipl. ECVP Professor Department of Pathology Faculty of Veterinary Medicine Centre for Fundamental and Applied Research for Animals & Health (FARAH) Liège...

Read more: Mutien Garigliany, Professor - Daniel Desmecht, Professor

FARAH - ULiège 
" As of today, one of the most promising therapeutic solutions against COVID-19 is the use of convalescent plasma. A subset of the antibodies present in this plasma are able to bind the surface proteins of the virus, chiefly the Spike (attachment) protein, and to neutralize the ability of viral particles to infect permissive cells. Upon request of the Red Cross and ULiège CHU hospital, we developed seroneutralization assays to determine the titers in neutralizing antibodies of convalescent plasma. In collaboration with KU Leuven (Rega) and ITM Antwerp, we just completed an interlaboratory ring test. We screen convalescent plasmas on a routine basis for the Croix Rouge and Rode Kruis. Only plasmas with a titer in neutralizing antibodies above the cut-off value will be used therapeutically. The scarcity of the scientific literature on the subject (only a few studies on the therapeutic use of convalescent plasmas are currently available) make it difficult to fix a cut-off...

Read more: Mutien Garigliany, Professor - Daniel Desmecht, Professor